Fraud office looks at GSK

Share this article:

GlaxoSmithKline is under investigation by the United Kingdom's Serious Fraud Office. The drugmaker announced the investigation Tuesday and said in a statement that it is “committed to operating its business to the highest ethical standards,” and will cooperate with the government investigation.

The New York Times reported that neither GSK nor the UK agency would discuss just what is being investigated, but noted the string of allegations of misconduct by authorities in China, the most recent one being accusations that GSK employee Mark Reilly implemented a bribery scheme in China.

The company has also been accused of misconduct in Iraq, Jordan and Lebanon, among other locations.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.